Todd M. Morgan, M.D. is a urological surgeon and Chief of Urologic Oncology at Michigan Medicine. Dr. Morgan is originally from Seattle, WA and completed his undergraduate and medical training at Harvard University. He returned to the Northwest in 2003 for his urology residency at the University of Washington, before moving to Nashville for his fellowship training in urological oncology at Vanderbilt University. In addition to being a clinician and surgeon, Dr. Morgan is a translational surgeon-scientist. His research involves developing blood-based tests that can guide precision-based treatments for prostate cancer in real time, and he is principal investigator of two large randomized controlled trials evaluating tissue-based biomarkers in men with localized prostate cancer. Dr. Morgan has been the recipient of Young Investigator Awards from the Prostate Cancer Foundation, Society for Urological Oncology, National Comprehensive Cancer Network (NCCN), and Society for Basic Urology Research. He has served on a number of national guideline committees, such as the AUA Muscle-Invasive Bladder Cancer Guidelines, the AUA Advanced Prostate Cancer Guidelines, the NCCN Prostate Cancer Early Detection Guidelines, The ASCO Localized Prostate Cancer Guidelines, and the ASCO Molecular Markers for Prostate Cancer Guidelines.
Most importantly, Dr. Morgan is dedicated to caring for patients with genitourinary cancers. His urologic oncology practice includes caring for patients with prostate, bladder, kidney, and penile cancers, and his surgical expertise encompasses a wide spectrum of open, laparoscopic, and advanced robotic surgical approaches. He has substantial expertise in cancer genetics and the use and interpretation of molecular biomarkers, which can help guide individualized treatment choice for some patients.
Beyond work, he loves his time enjoying the great town of Ann Arbor and beautiful state of Michigan with his wife, Wendy, and their two boys. Whether camping in Petoskey, sitting on a beach in Grand Haven, or biking around the neighborhood in Ann Arbor, the Morgan family knows that life in the Midwest is hard to beat.
Areas of Interest
Dr. Morgan runs a translational research laboratory focused on identifying biomarkers associated with treatment response, primarily through molecular profiling of tumor cells circulating in the blood and bone marrow of men with prostate cancer. The goal of this work is to be able to use a “liquid biopsy” to inform decisions in the same way that tissue-based biopsies currently do. These efforts also seek to shed light on how tumors learn to evade certain treatments and how these resistance mechanisms can be targeted. Dr. Morgan also directs a number of clinical trials, primarily focused on understanding how cancer biomarkers can be utilized in order to provide more individualized management approaches. His research has received funding from the National Cancer Institute (NCI), the Department of Defense, the Prostate Cancer Foundation, the Taubman Institute, and the National Comprehensive Cancer Network, among others.
Prostate Cancer: including robotic prostatectomy and active surveillance
Bladder Cancer: including bladder preservation approaches as well as open and robotic radical cystectomy
Kidney Cancer: Including open and robotic approaches, and nephron-sparing (i.e. partial nephrectomy) when appropriate
Penile Cancer: including robotic inguinal lymphadenectomy
Medical School or Training
- Harvard Medical School, 2003
- University of Washington Medical Center, Surgery General, WA, 2004
- University of Washington Medical Center, Urology, WA, 2009
- Urologic Oncology, Vanderbilt University Medical Center, 2011
- American Urological Association
- Society of Urologic Oncology
- American Association of Cancer Research
- American Society of Clinical Oncology
- Southwest Oncology Group